Discovery of Bis-sulfonamides as Novel Inhibitors of Mitochondrial NADH-Quinone Oxidoreductase (Complex I).
Journal
ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073
Informations de publication
Date de publication:
09 Feb 2023
09 Feb 2023
Historique:
received:
01
12
2022
accepted:
16
01
2023
pmc-release:
09
02
2024
entrez:
16
2
2023
pubmed:
17
2
2023
medline:
17
2
2023
Statut:
epublish
Résumé
Mitochondrial oxidative phosphorylation (OXPHOS) is an essential cellular metabolic process that generates ATP. The enzymes involved in OXPHOS are considered to be promising druggable targets. Through screening of an in-house synthetic library with bovine heart submitochondrial particles, we identified a unique symmetric bis-sulfonamide, KPYC01112 (
Identifiants
pubmed: 36793437
doi: 10.1021/acsmedchemlett.2c00504
pmc: PMC9923842
doi:
Types de publication
Journal Article
Langues
eng
Pagination
211-216Informations de copyright
© 2023 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Science. 2015 Jan 2;347(6217):44-9
pubmed: 25554780
Signal Transduct Target Ther. 2020 Dec 18;5(1):288
pubmed: 33335095
J Med Chem. 2020 Dec 10;63(23):14276-14307
pubmed: 33103432
Nature. 2013 Feb 28;494(7438):443-8
pubmed: 23417064
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188534
pubmed: 33794332
Structure. 2018 Feb 6;26(2):312-319.e3
pubmed: 29395787
Biochemistry. 2007 May 29;46(21):6409-16
pubmed: 17474759
Nature. 2016 Aug 18;536(7616):354-358
pubmed: 27509854
Nucleic Acids Res. 2018 Jul 2;46(W1):W368-W373
pubmed: 29718451
J Med Chem. 2022 Jan 13;65(1):343-368
pubmed: 34982568
Curr Oncol Rep. 2021 Mar 17;23(4):49
pubmed: 33730242
Biochem Pharmacol. 2020 Dec;182:114253
pubmed: 33011159
ACS Med Chem Lett. 2022 Feb 18;13(3):348-357
pubmed: 35300083
J Med Chem. 2022 Feb 24;65(4):3404-3419
pubmed: 35167303
Front Oncol. 2021 May 10;11:653621
pubmed: 34041023